Kabraji Lab Publications

You’ll find research from the Kabraji Lab in numerous high-profile cancer journals.

Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases

Journal: Clinical Cancer Research, January 2023
Authors: Kabraji S, et al.
Citation: Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138.

Temporal and spatial topography of cell proliferation in cancer

Journal: Nature Cell Biology, March 2022
Authors: Gaglia, G, et al.
Citation: Nat Cell Biol. 2022 Mar;24(3):316-326. doi: 10.1038/s41556-022-00860-9.

Kabraji S, Lin NU. Keeping it in the family: HER3 as a target in brain metastases. Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107. Epub ahead of print. PMID: 37306554.
Bergholz JS, et al. PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature. 2023 May;617(7959):139-146. doi: 10.1038/s41586-023-05940-w. Epub 2023 Apr 19. PMID: 37076617.
Wang Q, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022 May 31;13(1):3022. doi: 10.1038/s41467-022-30568-1. PMID: 35641483; PMCID: PMC9156717.
Ni J, et al. p16^INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nat Commun. 2022 Mar 18;13(1):1473. doi: 10.1038/s41467-022-29081-2. PMID: 35304445; PMCID: PMC8933392.
Bergholz JS, et al. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Clin Cancer Res. 2020 Nov 1;26(21):5557-5566. doi: 10.1158/1078-0432.CCR-19-2300. Epub 2020 Jun 23. PMID: 32576627; PMCID: PMC7641965.

AKT1^low quiescent cancer cells in ductal carcinoma in situ of the breast

Journal: NPJ Breast Cancer, March 2019
Authors: Kabraji S, et al.
Citation: NPJ Breast Cancer. 2019 Mar 21;5:10. doi: 10.1038/s41523-019-0105-y

AKT1^low Quiescent cancer cells promote solid tumor growth

Journal: Molecular Cancer Therapeutics, January 2018
Authors: Alves CP, et al.
Citation: Mol Cancer Ther. 2018 Jan;17(1):254-263. doi: 10.1158/1535-7163.MCT-16-0868

Liu Z, et al. Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. Sci Rep. 2019 Jan 24;9(1):622. doi: 10.1038/s41598-018-36874-3. PMID: 30679540; PMCID: PMC6346002.
Kabraji S, et al. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res. 2018 Apr 15;24(8):1795-1804. doi: 10.1158/1078-0432.CCR-17-3351. Epub 2018 Feb 6. PMID: 29437794; PMCID: PMC5899637.
Kabraji S, et al. AKT1^low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res. 2017 Aug 1;19(1):88. doi: 10.1186/s13058-017-0877-7. PMID: 28764807; PMCID: PMC5540189.

Contact the Kabraji Lab

Email: Sheheryar.Kabraji@RoswellPark.org
Office phone: 716-845-3429
Admin fax: 716-845-4620
Office location: Medical Research Complex - Room 458

Department of Molecular & Cellular Biology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263